Tagged with GSK,

UK The latest UK pharma news, including how new investment in GSK stands to reshape the country’s iconic pharma giant; CDMO Sterling’s latest acquisition; and calls for a national registry to capture company payments to clinicians and patient support groups.   The 30 fastest-growing unquoted pharma companies in the UK (Consultancy.uk)…

Vaccines The story of how British doctor Edward Jenner serendipitously discovered a way to inoculate people against smallpox in 1976 by injecting them with cowpox pus is well-known. Over the past two centuries, vaccine development platforms have (thankfully) advanced leaps and bounds, delivering a wealth of options to tackle global health…

Global The Top 20 companies on the 2021 Access to Medicines Index ranked on governance of access, research and development, and product delivery indices. Compiled by the Access to Medicine Foundation, the report measures how well the largest 20 global Big Pharma companies are making drugs and vaccines accessible to low-…

Global Four companies (GSK, Pfizer, Sanofi, and MSD) together occupy over 80 percent of the global market for vaccines. Moreover, vaccines are an important part of these companies’ revenue streams, making up between 13 and 21 percent of total revenues in 2019.   Made with Visme Infographic Maker   Insights on Vaccines’…

Norway Many countries have struggled to adapt to the shift to remote working and digital communication brought about by the COVID-19 pandemic and subsequent lockdowns. However, these tools were already well-utilised in the vast but sparsely populated country of Norway and digital is increasingly being seen as a key component in…

Norway Christian Probst gives an overview of GSK Norway’s broad portfolio, market access hurdles, and the importance of bringing clinical trials back to Norway. Probst also touches on how the country’s impressive digital footprint can be better leveraged and GSK’s role in Norway as one of the world’s leading vaccine companies.…

Global 2020 was a challenging year globally, but one in which the importance of the healthcare and life sciences sector was underlined like never before. Despite lockdowns and travel restrictions, PharmaBoardroom still managed to talk to key industry stakeholders from across the world helping shape the future of global health. Featured…

Global During the FT Global Pharmaceutical and Biotechnology Conference last week, GSK global vaccines president Roger Connor shared some of his insights regarding the reorganization of GSK’s Consumer Health, Pharmaceuticals and Vaccines business units, their pandemic adjuvant system technology, and their – and the industry’s overall – commitment to COVID-19 vaccine…

GSK GSK, the world’s largest manufacturer of vaccines, has pursued a different strategy to that of its contemporaries in the effort to develop a safe, effective, and mass-producible COVID-19 vaccine. PharmaBoardroom recently spoke to Emmanuel Hanon, GSK’s senior VP for vaccines R&D, to get his take on the company’s unique role…

Belgium In an exclusive interview, GSK’s Senior VP for Vaccines R&D Dr Emmanuel Hanon discusses how the sharing of GSK’s adjuvant technology with a wealth of scientific institutions and companies globally can contribute to the rapid development of a safe and effective COVID-19 vaccine. Dr Hanon outlines the challenges inherent in…

Vaccines Vaccines are back on top of the pharma priority list as companies race against the clock to develop the first effective COVID-19 vaccine. Below we present the top 10 pharma companies producing vaccines globally, based on revenues from 2017 and projected revenues from 2024. GSK leads the pack with over…

Opinion Mike Glover, Vice President Global Head of Access and Pricing Strategy Oncology at GSK outlines that while new mathematical approaches to health technology assessment (HTA) have been hugely beneficial, a broader approach that includes the insights of individual people is necessary to truly drive forward better health outcomes.   The…